📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. (2022)

First Author: Turkova A

Attributed to: Blood borne viruses funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2352-3018(22)00160-6

PubMed Identifier: 35868341

Publication URI: http://europepmc.org/abstract/MED/35868341

Type: Journal Article/Review

Volume: 9

Parent Publication: The lancet. HIV

Issue: 9

ISSN: 2352-3018